Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
22/07/2026 22:58
BRIEF-Keros Therapeutics - Keith Regnante Resigns As CFO July 22 (Reuters) - Keros Therapeutics Inc KROS.O:
KEROS THERAPEUTICS - KEITH REGNANTE RESIGNS AS CFO EFFECTIVE AUGUST 3, 2026 - SEC FILING
KEROS THERAPEUTICS - APPOINTS ANNITA TANINI INTERIM PRINCIPAL FINANCIAL OFFICER EFFECTIVE AUGUST 4, 2026 - SEC FILING
Source text: [ID:n0001664710-26-000038]
Further company coverage: KROS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops